MACNICA,-INC.
7.11.2016 11:02:05 CET | Business Wire | Press release
Macnica, Inc., a global leader in distributing semiconductors, electronic components, and network equipment, with its headquarter located in 1-6-3 Shin-Yokohama, Kohoku-ku, Yokohama, Japan (“Macnica”), today expanded its Mpression IP portfolio releasing SLVS-EC interface IP core for ALTERA FPGA compliant with SLVS-EC interface technology newly incorporated into Sony CMOS Image Sensor. Users can quickly develop and introduce their products early into market with SLVS-EC technology.
Macnica is a global, technology oriented distributor particularly focusing on demand creation. Macnica not only offers outstanding technical support for its product lines but also provides its original products and services under its “Mpression” brand for satisfying customer needs and solving issues.
Sony CMOS Image Sensor with SLVS-EC interface capable of high speed data
transfer will be introduced into CMOS Image Sensor market to satisfy
needs for trending higher resolution and higher framerate.
Mpression
SLVS-EC Rx IP Macnica has developed can support and contribute users who
develop advanced products supporting SLVS-EC interface.
Macnica has paid attention to SLVS-EC interface in the early days and
realized a world first solution to receive high speed image data
transmitted over SLVS-EC interface on ALTERA FPGA.
Now, the IP
enables to connect Sony high resolution and high framerate CMOS Image
Sensor to FPGA easily. It is ideal for a various applications like the
products with CMOS image sensor and FPGA to receive the image data.
Macnica is licensing the IP worldwide through its subsidiaries or
partners. ATD Electronique, an affiliate of Macnica sells and supports
it in Europe.
Macnica will exhibit demonstration of SLVS-EC Rx IP
at the booth of ATD Electronique in VISION SHOW held in Stuttgart,
Germany from November 8 to 10. Please don’t forget to visit us.
|
VISION SHOW Information |
||
| Name of Exhibition |
VISION
Leading world trade fair for machine vision |
|
| Schedule | 08 - 10 November 2016 | |
| Place | Messe Stuttgart | |
| Booth No. of ATD Electronique | Hall 1, E82 | |
* All company names and product names mentioned herein are trademarks or registered trademarks of their respective owners.
About Macnica:
Macnica has been established since 1972 as a semiconductor distribution company headquartered in Yokohama, Japan servicing customers in Japan, the Americas and Asia through its 75 sales offices around the world. Total number of employees is over 2,000 worldwide and total revenue for fiscal 2015 was approximately US$4B. Macnica is famous for having an excellent engineering team of more than 800 application engineers with strong focus on providing technical support for its customers. Macnica is continuing to improve its presence globally by having successful partners in strategic areas in the electronics market. Macnica Inc. and ATD Electronique have entered into an agreement for Macnica to acquire 49% of ATD’s outstanding shares on July 22nd, 2016.
About ATD Electronique:
ATD Electronique, who was founded in 1990 represents and distributes innovative electronic component brands and offers engineering services for machine vision and imaging applications through its offices in France and Germany and its representatives in Italy and Spain. Its product portfolio includes image sensors, controller & interface ICs, ISPs as well as development tools and design services enabling fast and efficient realization of new high performance camera systems for markets such as automotive, medical, security and machine vision.
About Mpression:
Mpression represents an integration and collection of all original
technology solutions of Macnica group such as software, platforms,
evaluation boards, and others which has been developed, provided and
supported in each country by each Macnica group companies.
Macnica
provides its advanced and ready-to-use system level solutions to
customers based on the accumulated know-hows by the very experienced
engineers from worldwide group companies, and thus leads to maximizing
the value of products as well as shortening customer's development time.
Macnica
is going to propose and support the IP offering one-stop services
through its group companies in all regions from country to country in
Europe, USA, China, and Asia.
Please visit our web-site (http://m-pression.com/
)
for a full detail of Mpression.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005041/en/
Contact:
Macnica, Inc.
Hajime Nakamura, 81-45-470-9838
Sales Planning,
Advanced Technology
AtdSpl@macnica.co.jp
FAX:
81-45-470-9857
Macnica Bldg No.2, 1-5-5 Shin-Yokohama, Kouhoku-ku,
Yokohama, 222-8563 JAPAN
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
